A single sperm donor who carries a rare cancer-causing genetic mutation has fathered at least 197 children across 14 ...

More than one-third of U.S. adults diagnosed with metastatic HER2-negative breast cancer in 2023 did not undergo testing for BRCA mutations, according to a retrospective analysis.Less than half ...

The first 100 bases of many genes show excess mutations, revealing a major genomic weak spot that shapes disease risk and ...

Tolmar, Inc. (Tolmar) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Rubraca® (rucaparib), enabling its use prior to chemotherapy for eligible ...

A hidden TP53 mutation in donor sperm raises concerns about gaps in genetic screening and long-term cancer risk in ...

Menin inhibitors target the interaction between menin and the KMT2A complex, offering a breakthrough in treating acute ...

A recent article in JAMA Internal Medicine describes a common genetic mutation found in many breast cancer patients who do ...

With a rate of mutation 35 percent higher than random chance, this previously unknown weakness could be a major vector for ...

The U.S. Food and Drug Administration has granted regular approval to treatment with Rubraca (rucaparib) for the treatment of ...

FZOCUS-1 assessed the safety and efficacy of fuzuloparib alone and in combination with apatinib for patients with newly diagnosed or advanced ovarian cancer.

Scientists discovered that the first 100 base pairs of human genes are unusually prone to mutations, especially during the earliest stages of embryonic development. These mosaic mutations often go ...

A new study reports that the locations where genes begin are particularly prone to mutations, and these genetic changes can be inherited by later generations. Researchers have identified previously ...